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Introduction Methods 
Conclusions 
We hypothesized that acute hyperglycemia (200 mg/dL) would increase H2O2 and 
decrease NO release in blood relative to saline control. By contrast, gp91ds-tat 
(RKKRRQRRR-CSTRIRRQL-Amide, MW=2452 g/mol, 1.2 mg/kg, Genemed Synthesis 
Inc., San Antonio, Tx), a cell-permeable peptide that selectively inhibits NADPH oxidase 
assembly/activation, would attenuate acute hyperglycemia-induced vascular dysfunction. 
Furthermore apocynin (MW=166 g/mol, Sigma Chemicals), another type of NADPH 
oxidase inhibitor, should have similar effects on H2O2 and NO blood levels as gp91ds-tat 
compared to hyperglycemia control, attenuating acute hyperglycemia-induced vascular 
dysfunction. 
We found that acute hyperglycemia significantly reduced blood NO compared to saline 
control. The addition of gp91ds-tat or apocynin with hyperglycemia significantly 
improved blood NO levels, similar to saline control. Meanwhile we found acute 
hyperglycemia maintained a higher level of H2O2 in blood compared to saline control. By 
contrast, gp91ds-tat or apocynin with hyperglycemia reduced blood H2O2 levels 
significantly compared to hyperglycemia. These results suggest that NADPH oxidase is a 
significant source of ROS overproduction and vascular endothelial dysfunction under 
acute hyperglycemic conditions, and that supplementation with gp91ds-tat or apocynin 
may be beneficial to attenuate hyperglycemia induced vascular endothelial dysfunction. 
Moreover, blood H2O2 levels in gp91ds-tat or apocynin treated groups were still 
significantly higher compared to that in saline groups. This may indicate that other 
sources of ROS exist such as in mitochondria, which will be further investigated.  
Results 
Male Sprague-Dawley rats (275 to 325g, Charles River, Springfield, MA) were anesthetized 
with 60 mg/kg of pentobarbital sodium with 1000 unit heparin via intraperitoneal (i.p.) 
injections. The jugular vein is catheterized in order to infuse intravenously with saline, 
20% D-glucose, 20% D-glucose with 1.2 mg/kg gp91ds-tat, or 20% D-glucose with 14 
mg/kg apocynin (see figure 3). The continuous infusion of 20% D-glucose solution is to 
maintain hyperglycemia at 200 mg/dL for about 180 min. gp91ds-tat and apocynin will 
be added to 20% glucose to reach approximately 20 µM and 1 mM in blood, respectively. 
Both femoral veins will be exposed and catheterized in order to place the calibrated NO 
and H2O2 microsensors (100μm, WPI Inc., Sarasota, FL) at random into each femoral 
vein (see figure 4). These microsensors will then be connected to the Apollo 4000 free 
radical analyzer (WPI Inc., Sarasota, FL) to measure for blood NO and H2O2 levels in 
real-time. NO, H2O2, and glucose levels will then be recorded at baseline and every 20 
minutes intervals throughout 180 minutes infusion period.  
The changes of blood NO and H2O2 levels will be expressed as the relative change to the 
baseline. Blood NO and H2O2 recording in picoAmps pA will be converted to the 
concentration (nM for NO and µM for H2O2) according to the corresponding calibration 
curve. All the data are represented as a mean ± SEM. The data was then analyzed by 
ANOVA using post hoc analysis with the Student Newman Keuls. P<0.05 was 
considered as significant. 
Hypothesis 
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Hyperglycemia (blood glucose ≥ 5.5 mM) and has been clearly linked to the development 
and progression of long-term microvascular, neurologic, and macrovascular 
complications in diabetic patients. Moreover, acute hyperglycemia such as during oral 
glucose tolerance tests and postprandially is also found to quickly and temporarily induce 
vascular endothelial dysfunction in non-diabetic subjects. Endothelial dysfunction is 
characterized by decreased endothelium-derived nitric oxide (NO) release and increased 
reactive oxygen species (ROS), such as superoxide (SO) and hydrogen peroxide (H2O2). 
Vascular NO is produced by endothelial NO synthase (eNOS) by converting L-arginine to 
L-citrulline in the presence of an essential cofactor tetrahydrobiopterin (BH4). NO is a 
potent vasodilator and facilitates blood flow. It has been proposed that the hyperglycemia 
induces eNOS uncoupling resulting in a shift from NO to SO production when BH4 is 
oxidized to dihydrobiopterin (BH2), which can further initiate inflammation and lead to 
micro/macro vascular complications. Recently non-phagocytic nicotinamide adenine 
dinucleotide phosphate (NADPH) oxidase has been highlighted because it may be 
activated first to initiate the other ROS production sources causing eNOS uncoupling 
(Figure 1). NADPH oxidase is a multi-subunit enzyme that catalyzes SO production by 
the reduction of molecular oxygen by using NADPH as an electron donor. In addition to 
neutrophils, where it was originally discovered, NADPH oxidase is also present in 
endothelial cells, vascular smooth muscle cells, fibroblasts, and some other cells [1].  The 
physiological nonphagocytic NADPH oxidase derived SO is normally produced in low 
concentrations and has been implicated in the regulation of migration, activation, 
proliferation, vascular tone, and vascular cell growth [1]. Hyperglycemia may stimulate 
SO production through a Protein Kinase C (PKC)-dependent activation of NADPH 
oxidase in vascular endothelial cells [2]. The role of NADPH oxidase in acute 
hyperglycemia induced vascular dysfunction and oxidative stress remains unclear. Our lab 
recently established a measurement of blood NO and H2O2 (i.e. indicator of ROS) in real 
time in an acutely induced hyperglycemia rat model. In this study, gp91ds-tat and 
apocynin, two NADPH oxidase inhibitors, will be utilized separately in this 
hyperglycemia rat model to explore the role of NADPH oxidase in hyperglycemia-
induced blood NO/H2O2 changes. gp91ds-tat peptide contains a docking sequence which 
is needed for p47phox binding to gp91phox. By contrast apocynin prevents p47phox 
binding to p22phox (Figure 2). Our lab found that gp91ds-tat and apocynin was effective 
in attenuating leukocyte-endothelial interactions in intravital microscopy (see abstract 
86389) and showed to be cardioprotective in myocardial ischemia/reperfusion (I/R) injury 
model (see abstract 86592).  
Figure 2. Oxidative stress under 
hyperglycemia, Modified from Wood 
et al., 2006. [4] 
Figure 3 – The catheterization of the jugular vein Figure 4 – Nitric oxide and hydrogen 
peroxide sensors in the femoral veins. 
Figure 1. Apocynin and Gp91 ds-tat inhibit the assembly of 
catalytic subunits of NADPH oxidase. Adapted and modified 
from Brandes RP 2003 [3]. 
Figure  5. Blood glucose level with time between saline and 20% glucose infusion groups. 
Figure 6. The comparison of blood NO levels relative to baseline among saline, 20% D-glucose, 20% D-glucose with 
gp91ds-tat,  and 20% D-glucose with apocynin (*p<0.05, **p<0.01 vs Glucose, # p<0.05, ## p<0.01 vs Saline). 
Figure 7. The comparison of blood H2O2 levels relative to baseline among saline, 20% D-glucose, 20% D-glucose 
with gp91ds-tat,  and 20% D-glucose with apocynin (*p<0.05, **p<0.01 vs Glucose, # p<0.05, ## p<0.01 vs Saline) 
Figure 8. The comparison of blood H2O2 levels relative to saline among  20% D-glucose, 20% D-glucose with 
gp91ds-tat,  and 20% D-glucose with apocynin (*p<0.05, **p<0.01 vs Glucose, # p<0.05, ## p<0.01 vs Saline). 
